The linear progression through generations of BTK inhibitors may be a flawed strategy, as indefinite kinase blocking is unsustainable. The future likely lies in BTK degraders, a new drug class that eliminates the target protein entirely, offering a novel approach to overcoming resistance instead of just inhibiting the protein.

While second-generation BTK inhibitors are clinically similar, the next major advance in combination therapy may come from the BCL2 inhibitor component. The newer agent sonrotoclax is potentially more potent and selective than venetoclax, which could lead to superior efficacy and tolerability in future regimens.

BTK degraders work despite most kinase inhibitor resistance mutations. However, resistance to degraders themselves alters the BTK binding pocket so significantly that subsequent targeting with any BTK kinase inhibitor is unlikely to be effective, positioning them as a potential end-of-line therapy.

A new agent, BGP-16673, works by destroying the BTK protein rather than just inhibiting it. This novel "degrader" mechanism is highly effective (75% response rate) in CLL patients who have developed resistance to covalent (e.g., ibrutinib), non-covalent (pirtobrutinib), and BCL-2 inhibitors, offering a new path for refractory disease.

Current oral BTK/BCL-2 inhibitor combinations for CLL have hit an MRD clearance "wall" of 35-50%. By upgrading the BCL-2 inhibitor to the more potent somatoclax, combined with zanubrutinib, MRD clearance rates nearly double to 98%, demonstrating that improving the BCL-2 component is key to achieving deeper remissions.

The traditional "germinal center" (GC) classification for DLBCL is overly simplistic. Molecular analysis reveals distinct subtypes within GC, such as "dark zone" and "light zone" signatures, which have different prognoses and responses to targeted therapies like polatuzumab.

BTK inhibitors block B-cell receptor signaling, causing long-surviving CLL cells to undergo programmed cell death (apoptosis) from a lack of stimulation. The common side effects are due to off-target kinase inhibition, not the intended BTK blockade itself, which has negligible action on other cells.

Long-term follow-up from the pivotal epcoritamab trial reveals that 46% of DLBCL patients who achieve a complete remission maintain it at four years. This durability provides strong evidence that bispecific monotherapy, not just CAR-T, can be a curative treatment for a subset of patients.

A new class of oral drugs, BCL6 degraders, are demonstrating complete remissions as a single agent in heavily pretreated aggressive lymphoma patients. This activity was surprising, as they were initially expected to require combination therapy to be effective, signaling a promising new non-cell surface targeting mechanism.